Crossmark

The place of S-ketamine in fibromyalgia treatment (ESKEFIB): study protocol for a prospective, single-center, double-blind, randomized, parallel-group, dose-escalation controlled trial

Crossref DOI link: https://doi.org/10.1186/s13063-021-05814-4

Published Online: 2021-11-27

Published Print: 2021-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Javorcikova, Zuzana https://orcid.org/0000-0003-2390-7804
Dangoisse, Michel

Nikis, Stéphane

Lechat, Jean-Paul

Gillain, Aline

Fils, Jean-François

Van der Linden, Philippe
License Information

Text and Data Mining valid from 2021-11-27

Version of Record valid from 2021-11-27
More Information

Article History

Received: 25 December 2020

Accepted: 10 November 2021

First Online: 27 November 2021

Declarations

:

: The study received approval from the ethics committee of the Grand Hôpital de Charleroi, Belgique () on October 8, 2020 (internal protocol reference G-1-2020-E020). The trial is registered with(NCT04436250). Patients meeting the inclusion criteria will sign a consent form after receiving oral and written information.

: All authors have consented to publication of this article and approved the final manuscript.

: The authors declare that they have no competing interests.

Document is current

Any future updates will be listed below